JRC Publications Repository

JRC Publications Repository >

Browsing by Author MORGENSTERN Alfred

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:   
Sort by: In order: Results/Page Authors/Record:
Showing results 26 to 45 of 136
Publication YearTitleAuthor(s), Editor(s), Other Contributor(s)Publication Type
2012Clinical aspects and future advances of targeted alpha therapy in oncologyKRATOCHWIL Clemens; GIESEL Frederik; MORGENSTERN AlfredContributions to Conferences
2012Combined 213Bi-DTPA- F3 and paclitaxel treatment of peritoneal spread of human ovarian carcinoma in a mouse model enhances therapeutic efficacy due to enhanced induction of apoptosis and G2/M phase cell-cycle arrestSEIDL C.; VALLON M.; BLECHERT B.; GILBERTZ K.-P.; AICHLER M; FEUCHTINGER A; GÄRTNER Florian; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; ESSLER M.Contributions to Conferences
2013Comparative analysis of alpha radioimmunotherapy with bismuth-213-labeled anti-CD138 antibody and Melphalan chemotherapy for the treatment of multiple myeloma.GOUARD S.; PALLARDY A; GASCHET J; FAIVRE-CHAUVET A; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; MAUREL C; KRAEBER BODÉRÉ F; BARBET J; DAVODEAU F, et alContributions to Conferences
2014Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy.GOUARD S.; PALLARDY A; GASCHET J; FAIVRE-CHAUVET A; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; MAUREL C; MATOUS E; KRAEBER BODÉRÉ F; DAVODEAU F, et alArticles in Journals
2014Comparison of the alpha-decay half-life of 210Po implanted in a copper matrix at 4.2 and 293 KPOEML PHILIPP; BELLONI F.; D'AGATA Elio; COLINEAU Eric; MORGENSTERN Alfred; GRIVEAU Jean-Christophe; RONDINELLA Vincenzo; REPNOW R; NASSISI V.; BENNEKER P, et alArticles in Journals
2012Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer modelGUSTAFSSON Anna; BAECK Tom; ELGQVIST Joergen; JACOBSSON Lars; HULTBORN Ragnar; ALBERTSSON Per; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; JENSEN Holger; LINDEGREN StureArticles in Journals
2006Control of Prostate Cancer Spheroid Growth Using (213)Bi-labeled Multiple Targeted Alpha RadioimmunoconjugatesWANG J.; RIZVI S.m.a.; MADIGAN C.; COZZI P.j.; POWER C.a.; QU C.f.; MORGENSTERN ALFRED; APOSTOLIDIS CHRISTOS; RUSSEL P.j.; ALLEN B.j., et alArticles in Journals
2009Cross Sections of the Reaction 231Pa(d,3n)230U for Production of 230U/226Th for Targeted Alpha TherapyMORGENSTERN Alfred; LEBEDA O.; STURSA J.; CAPOTE R.; SIN M.; BRUCHERTSEIFER Frank; ZIELINSKA Barbara; APOSTOLIDIS ChristosArticles in Journals
2008Cross-sections of the Reaction 232Th(p,3n)230Pa for Production of 230U for Targeted Alpha TherapyMORGENSTERN Alfred; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank; CAPOTE R.; GOUDER Thomas; SIMONELLI Federica; SIN M.; ABBAS KamelArticles in Journals
2005Cyclotron Production of Ac-225 for Targeted Alpha TherapyAPOSTOLIDIS CHRISTOS; MOLINET Roger; MCGINLEY JOHN; ABBAS KAMEL; MOELLENBECK J.; MORGENSTERN ALFREDArticles in Journals
2005Cyclotron Production of Ac-225 for Targeted Alpha TherapyAPOSTOLIDIS CHRISTOS; MOLINET Roger; MCGINLEY JOHN; MOELLENBECK J.; MORGENSTERN ALFRED; ABBAS KAMELArticles in Journals
2008The Cytokinesis-Block Micronucleus Assay as a Biological Dosimeter for Targeted Alpha TherapySONG E.; RIZVI S.; QU C. F.; RAJA C.; YUEN J.; LI Y.; MORGENSTERN ALFRED; APOSTOLIDIS CHRISTOS; ALLEN B. J.Articles in Journals
2006Cytotoxicity of PAI2, C595 and Herceptin Vectors Labeled with the Alpha-Emitting Radioisotope Bismuth-213 for Ovarian Cancer Cell Monolayers and ClustersSONG Y.j.; QU C.f.; RIZVI S.m.a.; LI Y.; ROBERTSON G.; RAJA C.; MORGENSTERN ALFRED; APOSTOLIDIS CHRISTOS; PERKINS A.c.; ALLEN Barry J.Articles in Journals
2013Decay data measurements on 213Bi using recoil atomsMAROULI MARIA; SULIMAN GABRIEL; POMME Stefaan; VAN AMMEL Raf; JOBBAGY VIKTOR; STROH HEIKO; DIKMEN H.; PAEPEN Jan; DIRICAN A.; BRUCHERTSEIFER Frank; APOSTOLIDIS Christos; MORGENSTERN AlfredArticles in Journals
2008Development and Evaluation of Peptidic Ligands Targeting Tumor-associated Urokinase Plasminogen Activator Receptor (uPAR) for Use in Alpha-emitter Therapy of Disseminated Ovarian CancerKNOER S.; SATO S.; HUBER T.; MORGENSTERN ALFRED; BRUCHERTSEIFER FRANK; SCHMITT M.; KESSLER H.; SENEKOWITSCH-SCHMIDTKE R.; MAGDOLEN V.; SEIDL C.Articles in Journals
2013Development of a high-activity 225Ac/213Bi radionuclide generator for synthesis of clinical doses of 213Bi-labelled biomoleculesBRUCHERTSEIFER Frank; APOSTOLIDIS Christos; MIRZADEH Saed; BOLL Rose; MURPHY Karen; MORGENSTERN AlfredContributions to Conferences
2013Die Alpha-Emitter Radioimmuntherapie des multiplen Myeloms mit 213Bi-CHX-A“-DTPA-anti-CD38 Immunkonjugaten zeigt eine hohe Effizienz im präklinischen Xenograft-ModellTEILUF K; SEIDL C.; BLECHERT B.; GÄRTNER Florian; GILBERTZ K.-P.; FERNANDEZ V; BASSERMANN F; ENDELL J; BOXHAMMER R; AICHLER M; FEUCHTINGER A; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; ESSLER M.Contributions to Conferences
2012Die intravesikale Radioimmuntherapie mit Bi-213-anti-EGFR Immunkonjugaten verursacht keine Schäden am UrothelMÜLLER Felix; SEIDL C.; WEIRICH G; RÖTZER S; FAZEL J; FRANK Annette; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SENEKOWITSCH-SCHMIDTKE R.Contributions to Conferences
2013DNA double strand break assessment as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor radiotherapyGRAF Franziska; FAHRER Jörg; MAUS Stephan; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; VENKATACHALAM S.; FOTTNER C.; WEBER Matthias M.; HUELSENBECK Johannes; SCHRECKENBERGER M; KAINA B; MIEDERER MatthiasContributions to Conferences
2013DNA double strand break assessment by yH2AX-foci quantification after alpha-particle emitter Ac-225 and electron emitter Lu-177 somatostatin receptor targeted radiotherapy correlates with cell death and apoptosis in vitroGRAF Franziska; FAHRER Jörg; MAUS Stephan; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; VENKATACHALAM S.; FOTTNER C.; WEBER M.m.; HUELSENBECK Johannes; SCHRECKENBERGER M; KAINA B; MIEDERER MatthiasContributions to Conferences
Showing results 26 to 45 of 136

 

The mission of the JRC is to provide customer-driven scientific and technical support for the conception, development, implementation and monitoring of EU policies. As a service of the European Commission, the JRC functions as a reference centre of science and technology for the Union. Close to the policy-making process, it serves the common interest of the Member States, while being independent of special interests, whether private or national.
Powered by DSpace
Top